Novel subcutaneous cytarabine infusion with the Omnipod system in dogs with meningoencephalomyelitis of unknown etiology
AMERICAN JOURNAL OF VETERINARY RESEARCH, 83(9).
MeSH headings : Animals; Area Under Curve; Chromatography, High Pressure Liquid / veterinary; Cytarabine / therapeutic use; Dogs; Half-Life; Humans; Infusions, Intravenous / veterinary; North Carolina
TL;DR:
An SC continuous-rate infusion of cytarabine via the Omnipod system is feasible in dogs and was able to achieve a steady-state concentration of more than 1 μg/mL 4 to 10 hours postinitiation of cyTarabine and a Cmax of 7,510 ng/mL, comparable to values reported previously with IV continuous- rate infusion administration in healthy research Beagles and dogs with meningoencephalomyelitis of unknown etiology.
(via
Semantic Scholar)
UN Sustainable Development Goal Categories